Chapter 15: Antimicrobial Drugs
Foundations of Antimicrobial Modern Medicine
Antimicrobial drugs are therapeutic agents used to fight infections caused by various microorganisms, including bacteria, viruses, fungi, and parasites.
They serve as the cornerstone of modern medicine.
According to the U.S. Centers for Disease Control and Prevention (CDC):
Antimicrobials are among the most commonly prescribed drugs in the United States.
More than million prescriptions for antibiotics are written each year.
Annually in the United States, there are approximately million infections caused by antibiotic-resistant bacteria.
About people die per year as a result of these resistant infections.
Terminology and Classification of Antimicrobial Drugs
Antimicrobial: Derived from Greek words anti (against), mikros (little), and bios (life). Refers to all agents that act against microbial organisms.
Antibiotic: Derived from Greek words anti (against) and biotikos (concerning life).
By strict definition, antibiotics refer to substances produced by microorganisms that act against another microorganism.
This definition excludes synthetic substances (e.g., sulfonamides and quinolones) and semisynthetic substances (e.g., methicillin and amoxicillin).
Target-Based Categorization:
Antibacterial drugs: Treat bacterial infections.
Antiviral drugs: Target viral infections.
Antifungal drugs: Target fungal infections.
Antiparasitic drugs: Treat protozoan and helminthic (worm) infections.
Historical Development of Antimicrobials
Before antimicrobial drugs, routine infections were often fatal:
Strep throat could cause death.
Infections were the primary cause of war-related deaths throughout most of history.
Tonics and potions claiming to cure infections existed for hundreds of years, but the first safe and effective drugs only appeared in the 20th century.
Alexander Fleming (1928):
Studied Staphylococcus aureus.
Observed a culture plate contaminated with mold where S. aureus was unable to grow near the mold.
He determined the mold excreted a compound that inhibited bacteria, which he named penicillin after the Penicillium species of mold.
Mass Production:
Penicillin was mass-produced by 1940 due to the onset of World War II.
It was primarily used to combat streptococcal and staphylococcal infections that caused high death tolls among soldiers.
Streptomycin:
Isolated from a culture of the soil bacterium Streptomyces griseus.
Found to be effective against tuberculosis.
Spectrum of Activity and Effects on Bacteria
Spectrum: The selective effect of antimicrobial drugs regarding which microbes they affect.
Broad-spectrum drugs: Effective against both Gram-negative and Gram-positive bacteria.
Examples: Levofloxacin and Ciprofloxacin.
Narrow-spectrum drugs: Effective against a limited range of bacteria.
Examples: Bacitracin and Vancomycin.
Preservation of Microbiota:
Narrow-spectrum drugs are generally preferred because they cause less disruption to the normal microbiota.
Using these requires a firm identification of the causative pathogen.
Bacteriostatic vs. Bactericidal:
Bacteriostatic: Prevents bacteria from growing.
Typically targets bacterial protein synthesis and metabolic pathways.
Bactericidal: Kills bacteria.
Typically targets bacterial cell walls, cell membranes, or nucleic acids.
Variable Effectiveness: A drug's status as bactericidal or bacteriostatic can change based on:
Pathogen type.
Dose.
Length of the drug regimen.
Pathogen load.
Route of administration.
Drawbacks of Bactericidal Drugs:
Elimination of normal microbiota.
Potential for a spike in bacterial toxin release (e.g., LPS from Gram-negatives), which can be deadly.
Natural, Synthetic, and Semisynthetic Drugs
Antibiotics: Naturally occurring antimicrobial compounds.
Synthetic antimicrobials: Manufactured by chemical processes.
Semisynthetic antimicrobials: Chemical modifications of naturally occurring antibiotics.
Modification involves adding chemical groups (e.g., R groups) to enhance desirable properties.
Example: Ampicillin and amoxicillin are derived by modifying Penicillin G. These modifications result in a broader spectrum (affecting Gram-negative bacteria) compared to the original Penicillin G, which only targets Gram-positive bacteria.
Drug Generations:
First-generation drugs: Result from a first round of chemical modification.
Second-generation drugs: Result from a second round of chemical modification.
Successive generations often feature extended spectrums, increased stability, and the ability to circumvent resistance mechanisms.
Factors Impacting Drug Development and Safety
Selective Toxicity: Antimicrobial drugs must kill the pathogen without harming the host.
Therapeutic Index: The ratio of the maximum tolerated (safe) dose to the minimum effective (therapeutic) dose.
A high therapeutic index is safer because the drug is effective well below the toxic threshold.
A narrow therapeutic index requires closer monitoring for toxicity.
Routes of Administration and Pharmacokinetics
Oral Administration:
Preferred due to ease of use.
Drug must be stable in gastric acid and absorbed in the intestines.
Parenteral Administration (Injection or Infusion):
Intravenous (IV): Into a vein.
Intramuscular (IM): Into muscle tissue.
Subcutaneous: Under the skin.
Downsides: Requires needles/IV lines, basic medical training, and may involve injection discomfort or phobia.
Half-Life ():
The time it takes for half of a dose to be eliminated or deactivated by the body.
Determines frequency of administration.
Short half-life (e.g., Penicillin V, minutes) requires frequent dosing (every 4 hours for 7–10 days).
Long half-life (e.g., Azithromycin, hours) requires infrequent dosing (every 24 hours for 3–5 days).
Antibacterial Drugs: Cellular Targets
Cell Wall Synthesis Inhibitors (Usually Bactericidal)
These drugs interfere with transpeptidation, which links peptide chains in peptidoglycan (N-acetylmuramic acid and N-acetylglucosamine).
Gram negative have less peptidoglycan. Negative has extra layer of outer membrane.
Penicillin blocks transpeptidase from building cross-link in the peptidoglycan wall, creating a weakened cell that cannot protect itself from bursting
This weakens the cell wall, leading to cell lysis.
Most effective during the exponential growth phase.
Beta-Lactam Antimicrobials
Characterized by a four-sided beta-lactam ring.
Pathogens may produce beta-lactamases, enzymes that inactivate these drugs.
Penicillins (suffixes end in -cillin):
Penicillin G: Natural, injected (acid-labile), targets Gram-positives and some gram-negatives
Penicillin V: Natural, oral.
Amoxicillin/Ampicillin: Semisynthetic, extended spectrum (Gram-negative coverage).
Cloxacillin/Dicloxacillin/Methicillin: Bulky R-groups provide steric hindrance against beta-lactamases; no expanded spectrum.
Note: MRSA (Methicillin-resistant S. aureus) and ORSA (Oxacillin-resistant S. aureus) altered their transpeptidase enzymes to avoid targeting.
Cephalosporins (prefixes cef- or ceph-):
Five generations; later generations have expanded Gram-negative activity and decreased Gram-positive activity.
Fifth-generation (e.g., ceftaroline) can combat MRSA/ORSA.
Common for patients with penicillin allergies.
Carbapenems (suffixes end in -penem):
Broad-spectrum; examples include Doripenem, Imipenem, Meropenem.
Rising resistance: CRE (Carbapenem-resistant Enterobacteriaceae) like Klebsiella pneumoniae and E. coli.
Monobactams:
Narrow-spectrum; example: Aztreonam.
Non-Beta-Lactam Cell Wall Inhibitors
Glycopeptides (e.g., Vancomycin, Teicoplanin):
Effective against Gram-positive organisms (MRSA).
Preferred for Clostridium difficile.
Side effects: "Red man syndrome" (itchy red flush), nephrotoxicity.
Bacitracin: Polypeptide; effective against Gram-positives; used in topical ointments (Neosporin).
Isoniazid: Interferes with mycolic acid synthesis in acid-fast bacteria (Tuberculosis treatment).
Nucleic Acid Synthesis Inhibitors (Usually Bactericidal)
Quinolones/Fluoroquinolones:
Synthetic drugs containing fluorine.
Target DNA replication enzymes (DNA gyrase and topoisomerases).
Ciprofloxacin: Effective against Mycobacterium and Pseudomonas.
Levofloxacin: Used for "walking pneumonia" (Mycoplasma pneumoniae).
Long half life - every 24 hours
Rifamycins (e.g., Rifampin):
Binds to RNA polymerase and inhibits transcription.
Effective against mycobacteria.
Can inhibit other drugs (digoxin, contraceptives, anticoagulants).
Folic Acid Synthesis Inhibitors (Antifolates; Usually Bacteriostatic)
Sulfa Drugs (Sulfonamides):
Broad-spectrum synthetic drugs.
Example: Sulfamethoxazole.
Often combined with Trimethoprim (TMP-SMX or Bactrim) for synergistic effect.
Protein Synthesis Inhibitors (Ribosome Targeting; Usually Bacteriostatic)
50S Subunit Binding:
Macrolides: Erythromycin, Clarithromycin, Azithromycin ("Z-Pak"). Broad-spectrum.
Lincosamides: Clindamycin.
Phenicols: Chloramphenicol.
30S Subunit Binding:
Tetracyclines (e.g., Doxycycline): Broad-spectrum. Side effects: Photosensitivity, bone/teeth effects in children under 8, risk of C. diff.
Aminoglycosides (suffixes -mycin or -micin): Narrow-spectrum (Gram-negative aerobic bacilli). Examples: Neomycin (topical), Gentamicin, Streptomycin. Side effects: Irreversible hearing loss and nephrotoxicity.
Plasma Membrane Disruptors (Usually Bactericidal)
Polypeptide Drugs (e.g., Polymyxin B, Colistin/Polymyxin E):
Target lipopolysaccharide (LPS) in Gram-negative outer membranes.
Narrow therapeutic index.
Used topically or as a last resort for multidrug-resistant infections (Pseudomonas aeruginosa, Acinetobacter baumannii).
Antiviral, Antifungal, and Antiparasitic Agents
Antiviral Challenges: Hard to target viruses without damaging host cells. Drugs primarily target active replication, not latent viruses.
Target categories: Attachment, penetration, uncoating, replication/assembly, release, and immune stimulation (interferons).
Remdesivir: First FDA-approved drug for COVID-19 (2020).
Antifungal Mechanisms:
Target ergosterol in plasma membranes (e.g., Azoles, Allylamines, Polyenes like Amphotericin B and Nystatin).
Target fungal cell wall synthesis (beta-glucan): Echinocandins (e.g., caspofungin acetate).
Antiprotozoan and Antihelminthic Drugs:
Difficult to develop because parasites are eukaryotes with complex life cycles.
Antimalarials: Chloroquine, Quinine.
Non-malarial: Metronidazole (Flagyl) for Toxoplasma, Giardia, Trichomonas.
Antihelminthic: Albendazole/Mebendazole (target microtubules/glucose uptake) and Praziquantel (paralyzes flukes/tapeworms).
Assessing Antimicrobial Sensitivity
Kirby-Bauer Test (Disk Diffusion):
Bacteria spread on Mueller-Hinton agar.
Antibiotic-infused disks are applied.
Zone of Inhibition: Clear area where growth is inhibited. Diameter is measured in millimeters ().
E-test: Determines the Minimum Inhibitory Concentration (MIC).
Interpretation:
Susceptible: Zone diameter falls in susceptible range.
Resistant: No zone or zone in resistant range.
Intermediate: Borderline response.
Questions & Clinical Case Scenarios
Think-pair-Share
Question: What structural feature of Gram-negative cell walls makes them harder for certain drugs to penetrate as compared to Gram-positive bacterial cell walls?
Answer Context: The outer membrane containing lipopolysaccharides (LPS) acts as an additional selective barrier in Gram-negative bacteria. Gram-positive bacteria have significantly more peptidoglycan in their cell walls than Gram-negative bacteria
Clinical Case Discussion (Chriscelle)
Data Provided:
Ampicillin: (Susceptible threshold ) \rightarrow Susceptible.
Erythromycin: (Intermediate range ) \rightarrow Intermediate.
Ceftriaxone: (Susceptible threshold ) \rightarrow Susceptible.
Ciprofloxacin: (Susceptible threshold ) \rightarrow Susceptible.
Questions:
a) What susceptibility test was done? The Kirby-Bauer (Disk Diffusion) test, as evidenced by the measurement of zone diameters in millimeters.
b) Based on the data, what drug(s) would you exclude? Erythromycin should be excluded as it shows only intermediate susceptibility, meaning the pathogen is not fully inhibited at standard doses.